BioPorto - katalog 2010

Product overview 2011

Diagnostics

Index BioPorto® Diagnostics The NGAL Test™ . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

NGAL ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Rapid NGAL ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Animal NGAL ELISA Kits . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

APC-PCI ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

MBL Oligomer ELISA Kit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

3 5 6 7 8 9

AntibodyShop® Cell biology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Coagulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Collectins and related products . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Complement . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Cytokines and hormones . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Enzymes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Marker molecules . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Microbiology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Miscellaneous . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Other blood proteins . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Sera and antigens . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

Abbreviations . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

10 11 11 11 13 14 14 14 15 15 15 16 16

Alphabetical product index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17 Ordering information . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19

ABOUT US BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector. The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney damage.

QUALITY POLICY BioPorto Diagnostics is committed to the highest level of quality in the manufacture, sale and support of its products. Quality and compliance with all applicable regulatory requirements and customer satisfaction must underlie the company’s efforts in manufacturing, advertising, sales, shipping and technical support.

BioPorto was founded in 2000 and is listed on NASDAQ OMX Copenhagen (symbol: BIOPOR).

BioPorto Diagnostics is committed to effectively implementing and continuously improving its quality management system in accordance with the European IVD directive, the Canadian medical device regulations and ISO 13485 requirements. BioPorto is ISO 13485:2003 certified and holds an ISO 13485:2003 certificate under CMDCAS.

Within the Company’s focus areas, BioPorto’s strategy is to develop new methods that can be patented and achieve a wide use in the diagnosis of various diseases.

BioPorto Diagnostics aims to please the customers while paying due regard to the interests of the company’s stakeholders.

2 Diagnostics

The NGAL Test™ – NGAL: changing the diagnosis and management of acute kidney injury (AKI) NGAL is a biomarker for diagnosing acute kidney injury (AKI). Its key advantage is that it responds earlier than other renal status markers like serum creatinine and shows a proportionate response to injury.

The NGAL Test™ is a particle-enhanced turbidimetric immunoassay for the quantitative determination of neutrophil gelatinase-associated lipocalin (NGAL) in human urine and EDTA plasma on automated clinical chemistry analyzers. NGAL measurements are useful in the diagnosis of acute kidney injury which may lead to acute renal failure. Using only a few drops of plasma or urine The NGAL Test™ gives you results in just 10 minutes and thus addresses the widespread demand for fast NGAL results.

3

Cat. No.

Product name

Contents

st001ca

IVD

The NGAL Test Reagent Kit

Immunoparticle Suspension, 7 mL Reaction Buffer, 35 mL

ST002CA

IVD

The NGAL Test™ Calibrator Kit

5 vials of 1 mL Prediluted calibrators

ST003CA

IVD

The NGAL Test™ Control Kit

6 vials of 1 mL Control Low, 3 x1 mL Control High, 3 x1 mL

Diagnostics

™

Clinical application · · · ·

Intensive care - monitoring Emergency room - triage tool Renal transplantation predictive evaluation Intravenous contrast agents assesing nephrotoxicity

Assay specifications Method

Particle-enhanced turbidimetric immunoassay

Sample

Urine and EDTA plasma

Sample stability

If the assay cannot be performed within 24 hours or specimens are to be shipped, freeze the specimens at −20°C or below.

For long-term storage of specimens, −70°C or below is recommended.

Calibrators

5 vials: 150, 600, 1500, 3000 and 5000 ng/mL Liquid ready-to-use

Controls

Low (200 ng/mL) and High (500 ng/mL) controls Liquid ready-to-use

Assay time

10 minutes

Shelf life

12 months

Open vial stability

30 days

On board stability

30 days (when refrigerated)

Measuring range

25 to 5000 ng/mL

LIMITATION The NGAL Test™ is meant to aid the diagnosis of kidney injury which may lead to acute renal failure.

However, The NGAL Test™ is not a stand-alone test as a variety of independent pathologies are associated with raised levels of urinary or plasma NGAL. Physicians must interpret the significance of any raised NGAL level in the light of the patient’s clinical features.

For in vitro diagnostic use in selected countries only. See www.bioporto.com for availability in your country.

Diagnostic use patented/patent pending in selected countries, WO2006066587.

See www.bioporto.com for an updated list of issued and pending patents.

4 Diagnostics

NGAL ELISA Kit – The preferred assay for NGAL measurement in laboratory research With the NGAL ELISA Kit (KIT 036), urine, plasma or serum samples can be analyzed with conventional ELISA equipment.

Cat. No.

Product name

Size

KIT 036

NGAL ELISA Kit

96 wells

WASH 036-30

25x Wash Solution Concentrate for KIT 036

30 mL

WASH 036-250

25x Wash Solution Concentrate for KIT 036

250 mL

Key features · · · · · · · · ·

5

Diagnostics

4-hour assay format Simple ELISA format - easy to perform Ready-to-use calibrators and working solutions Pre-coated ELISA strips All incubations performed at room temperature Easy storage All components are stored at 4°C Automation possible on open ELISA workstations For Research Use Only. Not for use in diagnostic procedures

NGAL Rapid ELISA Kit

†

IVD

*

– NGAL: the early biomarker for diagnosing acute kidney injury (AKI) Cat. No.

Product name

Size

KIT 037

NGAL Rapid ELISA Kit

96 wells

WASH 037-30

25x Wash Solution Concentrate for KIT 037

30 mL

WASH 037-250

25x Wash Solution Concentrate for KIT 037

250 mL

Key features · · · · · · · · ·

1 hour rapid assay format Simple ELISA format - easy to perform Ready-to-use calibrators and working solutions Pre-coated ELISA strips All incubations performed at room temperature Easy storage All components are stored at 4°C Automation possible on open ELISA workstations Assay dynamic range is 100-fold (0.2 – 20 ng/mL)

*For in vitro diagnostic use in selected countries only. See www.bioporto.com for availability in your country.

Diagnostic use patented/patent pending in selected countries, WO2006066587. See www.bioporto.com for an updated list of issued and pending patents.

†

6 Diagnostics

Animal NGAL ELISA Kits Evidence is rapidly accumulating to show that NGAL also rises in animals after kidney injury as in humans, where NGAL undergoes an early and dramatic up-regulation in renal tubular cells after kidney injury from a variety of causes. NGAL is then released into both urine and plasma and can be used in basic research, medical research as well as in preclinical drug development studies, to detect the extent of kidney injury.

7

Cat. No.

Product name

Size

KIT 042

Mouse NGAL ELISA Kit

Up to 40 samples in duplicate

KIT 043

Dog NGAL ELISA Kit

Up to 40 samples in duplicate

KIT 044

Pig NGAL ELISA Kit

Up to 41 samples in duplicate

KIT 045

Monkey NGAL ELISA Kit

In development

KIT 046

Rat NGAL ELISA Kit

Up to 40 samples in duplicate

Diagnostics

Key features · · · · · · · ·

Highly reproducible and easy to use Ready-to-use working solutions Ready-to-use calibrators Pre-coated 96-well ELISA plate All incubations performed at room temperature Easy storage All components are stored at 4°C Requires only standard ELISA equipment

APC-PCI ELISA Kit – APC-PCI: a potential marker for evaluating sepsis patients for APC treatment Activated protein C-protein C inhibitor (APC-PCI) complex starts being formed as soon as protein C (PC) is activated on the blood vessel wall and the active enzyme (APC) enters into contact with its specific circulating serpin, protein C inhibitor (PCI). The resulting inactive APC-PCI complex is thus a marker of PC activation.

Sepsis is a devastating condition characterized by systemic activation of the inflammatory and coagulation cascades in response to microbial infection. Apart from antimicrobial therapy, the infusion of human recombinant APC (Xigris®, Eli Lilly) is the only treatment documented to reduce the mortality of sepsis patients.

Key features

BioPorto Diagnostics’ APC-PCI ELISA Kit measures activated protein C–protein C inhibitor complex in human plasma. For Research Use Only. Not for use in diagnostic procedures.

·

Cat. No.

Product name

Size

KIT 040

APC-PCI ELISA Kit

96 wells

· ·

·

Highly reproducible and easy to use Precoated microwell strips that can be used as strips of 8 or as individual wells All incubations performed at room temperature Only standard ELISA equipment is required

8 Diagnostics

MBL Oligomer ELISA Kit

IVD

*

– a key test in the assessment of primary immunodeficiency Mannan-binding lectin (MBL) is an important component of the innate immune system. However, in at least 12% of the average Caucasian population, the circulating level of functional MBL is insufficient. This makes MBL deficiency by far the most common primary immunodeficiency. While the consequences of MBL deficiency can be quite subtle, several studies have shown that MBL deficiency increases susceptibility to infectious diseases and predisposes to greater severity when infections occur.

The MBL Oligomer ELISA Kit employs a monoclonal antibody sandwich which is highly specific for normally oligomerized MBL molecules. Hence the results obtained with the KIT 029 correspond to the circulating levels of “functional” MBL. Cat. No.

Product name

Size

KIT 029

MBL Oligomer ELISA Kit

96 wells

WASH 029-30

25x Wash Solution Concentrate KIT 029

30 mL

WASH 029-250

25x Wash Solution Concentrate KIT 029

250 mL

* For in vitro diagnostic use in selected countries only. See www.bioporto.com for availability in your country.

9

Diagnostics

Key features · · · · ·

Measures oligomerized “functional” MBL Measures in plasma and serum All reagents are ready-to-use Storage at 2-8°C Can be used in many different automated ELISA workstations

Monoclonal antibodies Antibodies are listed according to their antigen by product area and with information about package size, applications, catalog number and conjugation, when applicable.

All the antibodies are protein-A or protein-G purified and the unconjugated antibodies are delivered in a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.5 M sodium chloride and 15 mM sodium azide as preservative.

Conjugated antibodies are delivered at a concentration of 1 mg/mL in 10 mM phosphate buffer, pH 7.4, containing 0.14 M NaCl and 15 mM sodium azide.

If the antibody you are looking for has more than one clone, please visit our website www.bioporto.com/products or feel free to contact us at info@bioporto.com.

Cell biology

Perlecan CSI 001

Thrombospondin I

Tetranectin

Collagen I, III & V

HYB 130

CSI 006 CSI 007 CSI 008

Vitronectin

Fibronectin

CSI 002

CSI 003 CSI 004

CSI 005 HYB 051

Specificity

Application

Cat. No.

Collagen Type I (human, bovine, pig, sheep, dog, goat)

EL, WB, IH

CSI 008-01

Collagen Type III (human, dog, rat, kangaroo)

EL, WB, IH

CSI 007-01

Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine)

EL, WB, IH

CSI 006-01

Fibronectin (bovine)

EL, WB, IH, IP

CSI 005-22

Fibronectin (bovine, human)

EL, WB, IH, IP

>1 clone

Fibronectin (bovine, human, chicken)

EL, WB, IH, IP

CSI 005-17

Fibronectin (human)

EL, WB

HYB 051-05

Perlecan (bovine)

EL, IH, IP, AC, WB

>1 clone

Tetranectin (human)

EL, WB, IH

>1 clone

Thrombospondin I (bovine)

EL, IH, IP

CSI 002-65

Vitronectin (bovine, horse, rabbit)

EL, IH

CSI 004-18

Vitronectin (bovine, sheep)

EL, WB, IH, AP

CSI 004-27

Vitronectin (human)

EL, WB, IH

>1 clone

Vitronectin (human, dog, cat, rabbit, bovine)

EL, WB

CSI 003-21

Vitronectin (human, dog, cat, sheep)

EL, WB

CSI 003-08

10

Coagulation Specificity

Application

Cat. No.

Antithrombin III (human)

EL, WB

>1 clone

Antithrombin III (human, denatured)

EL, WB

HYB 228-12

Antithrombin III (human, native and denatured)

EL, IH

HYB 228-08

APC–AAT complexes, neoepitope (human)

EL

ABS 001-07

Aprotinin

EL, WB

>1 clone

Aprotinin, Biotinylated

EL

ABS 037-18B

D-dimer (human, dog)

EL

>1 clone

D-dimer (human, dog), Biotinylated

EL

ABS 015-22B

Factor IX (human, Christmas factor)

EL, WB

>1 clone

Fibrinogen (human)

EL, WB

>1 clone

Hirudin

EL, WB

>1 clone

Protein C (human)

EL, WB, IH

>1 clone

Protein S (human)

EL

HYB 232-11

Thrombin (human)

EL, WB

>1 clone

von Willebrand factor (human, vWf)

EL

>1 clone

Specificity

Application

Cat. No.

Collectin-43 (bovine, CL-43)

EL, WB

>1 clone

Conglutinin (bovine)

EL

HYB 263-02

H-Ficolin (human)

EL

RIG 334-01

H-Ficolin (human), Biotinylated

EL

RIG 334-01B

Glycoprotein-340 (human, gp-340)

EL, WB, IH

>1 clone

L-Ficolin (human)

EL, WB

>1 clone

M-Ficolin (human)

EL, IH

>1 clone

Surfactant protein A (human, hSP-A)

EL, WB, IH

HYB 238-04

Surfactant protein a (human, hSP-A), Biotinylated

EL

HYB 238-04B

Surfactant protein D (human, hSP-D)

EL, WB, IH

>1 clone

Surfactant protein D (human, hSP-D), Biotinylated

EL

HYB 246-04B

Specificity

Application

Cat. No.

Complement component C1-inhibitor (C1-INH)

EL

>1 clone

Complement component C1s (human, pro- and activated enzyme)

EL

>1 clone

Complement component C2 (human)

EL, WB

>1 clone

Complement component C3 (human)

EL, WB

>1 clone

Complement component C3 (human), beta-chain genetic variant

EL, WB

HAV 004-01

Complement component C3 (rat)

EL, IH

HYB 118-02

Complement component C3a/C3a desArg (human)

EL, WB

>1 clone

Complement component C3a/C3a desArg (human), Biotinylated

EL

GAU 017-01B

Complement component C4 (human)

EL, WB

>1 clone

Complement component C5 (human)

EL, WB

>1 clone

Complement component C5a/C5a(desArg) anaphylatoxin (human)

EL, WB

GAU 025-05

Collectins and related products

Complement

11

Complement (continued) Specificity

Application

Cat. No.

Complement component C5b-9

EL, IH

DIA 011-01

Complement component C5b-9, Biotinylated

EL

DIA 011-01B

Complement component C9 (human)

EL, WB

>1 clone

Complement factor B (caiman)

EL, WB

KSK 002-01

Complement factor B (chicken)

EL, WB

HYB 022-03

Complement factor B (human)

EL, WB

>1 clone

Complement factor B (human), Biotinylated

EL

HYB 008-06B

Complement factor D (human)

EL, WB

>1 clone

Complement factor D (human), Biotinylated

EL

GAU 008-01B

Complement factor H (human, ß1H-globulin)

EL, WB

>1 clone

Complement factor H (human, ß1H-globulin), Biotinylated

EL

>1 clone

Complement factor I (human)

EL, WB

>1 clone

Mannan-binding lectin (chicken, MBL)

EL, WB, IH

HYB 182-01

Mannan-binding lectin (human, horse, pig, MBL)

EL

HYB 131-14

Mannan-binding lectin (human, MBL)

EL, WB, IH

>1 clone

Mannan-binding lectin (human, MBL), Biotinylated

EL

HYB 131-01B

Mannan-binding lectin (rat, MBL)

EL

HYB 131-18

Properdin (human)

EL, WB

>1 clone

Properdin (human), Biotinylated

EL

HYB 039-04B

MBL

Classical Pathway

KIT 029 HYB 131

Lectin Pathway

H-Ficolin

Alternative Pathway

RIG 334

M-Ficolin ABS 036

C1-INH HYB 288

L-Ficolin C1q

ABS 005

MBL/Ficolin

C1q

B H2O

C1s

C1r

C1s

ABS 002

C3 (H2O)

MASP-2

MASP-1

C3

C3 (H2O) B

Carbohydrate

Carbohydrate

C2

D

C4

C3 (H2O) Bb

C3

HAV 004 HYB 005

C3a

C2b

HAV 005

Factor D GAU 010 GAU 008

HYB 050 C2

Factor B

C4a

Ba

Factor Ba/b HYB 008

Properdin (Factor P)

Properdin HYB 039 3

C3d

HAV 003 HYB 030

C4b2a

C2a

C4b C3bBb

C4

HYB 162-04

C3a/C3a (desArg)

C3

GAU 013 GAU 017

C5

C4b

C3a

C3a

HYB 162-02

C3bBb3b

C4b2a3b

HYB 029

C5a/C5a (desArg) GAU 025

C5 - C9 Membrane attack complex

HYB 268 GAU 018 GAU 020

C9

ABS 004

C5b-9

DIA 011

Factor H

Lysis or phagocytosis of the microorganism Factor I HYB 061

Overview of the complement system. The name of the component and BioPorto Diagnostics' catalog number are shown in the blue boxes.

12

Cytokines and Hormones

Glucagon-like peptide-1 (C-terminal amidated) HYB 147-08 HYB 147-12 HYB 147-13

ABS 033-04 ABS 033-10

HYB 011-05 N-terminal extension

HYB 147-06 ABS 046-03

HYB 011-05

N-terminus

ABS 033-04 C-terminus ABS 033-10

C-terminus

1 1

N-terminal extension

6 7

2

HYB 011-05

7 3

HYB 011-05

ABS 9033-041 ABS 033-10

1

37

6 7

36 amide

37

36 amide

37

N-terminus

6 7

HYB 147-08 HYB 2 147-12 HYB 147-13

HYB 147-06

7

C-terminus

2

GLP-1 Active form

6 7

3

GLP-1 Metabolite 9

7

36 (amide)

Specificity

Application

Cat. No.

Adrenomedullin (human)

EL

ABS 027-01

EL, IH

>1 clone

EL, WB

>1 clone

Estradiol-17-beta

EL

HYB 057-02

Exendin-4

EL

>1 clone

EL

>1 clone

Gastric Inhibitory Polypeptide (GIP)

EL, IH

>1 clone

Ghrelin (human)

EL

ABS 050-45

Ghrelin (human, rat)

EL

ABS 052-121

Ghrelin (human, rat), Biotinylated

EL

ABS 052-121B

Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific)

EL

HYB 011-05

Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific)

EL, IH

HYB 147-06

Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific), Biotinylated

EL

HYB 147-06B

Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific)

EL, IH

>1 clone

Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific), Biotinylated

EL

ABS 033-10B

Glucagon-like peptide-1 (GLP-1, Mid-molecule specific)

EL, WB, IH

>1 clone

Glucagon-like peptide-1 (GLP-1, Mid-molecule specific), Biotinylated

EL

>1 clone

Glucagon-like peptide-1 (GLP-1, Non-amidated (-Arg-Gly), C-terminal specific)

EL

ABS 046-03

Glucagon-like peptide-1 (GLP-1, Non-amidated (-Arg-Gly), C-terminal specific), Biotinylated

EL

ABS 046-03B

Glucagon-like peptide-2 (human, GLP-2)

EL

HYB 006-02

Leptin

EL, IH

>1 clone

Leptin, Biotinylated

EL

ABS 022-11B

Neuropeptide Y (human, rat, mouse, NPY)

EL, IH

ABS 028-08

Pancreatic Polypeptide (human, PP)

EL

ABS 030-06

2

3

alpha-calcitonin gene-related peptide (alpha-CGRP)

7

Chorionic gonadotrophin (human, hCG)

9

3

Exendin-4, Biotinylated

13

36

HYBamide 147-08 HYB 147-12 HYB 147-13

N-terminus

GLP-1 Extended form 1

N-terminal extension

ABS 044-491 ABS 044-53

N-terminal extension

ABS 033-04 1 ABS 033-10 1

N-terminus

9

36 (amide)

36 (amide)

HYB 1 HYB 1 HYB 1

Cytokines and Hormones (continued) Specificity

Application

Cat. No.

Peptide Histidine-Methionine (PHM)

EL

ABS 020-03

Peptide YY (human, PYY (3-36)(peptide tyrosine-tyrosine amide, 3-36))

EL

ABS 051-04

Peptide YY (human, PYY)

EL, IH

ABS 029-01

Peptide YY (human, PYY), Biotinylated

EL

ABS 029-01B

Tumor necrosis factor alpha (human, TNF-alpha)

EL

>1 clone

Vasoactive Intestinal Peptide (human, bovine, porcine, rat, VIP)

EL

ABS 023-02

Specificity

Application

Cat. No.

Alkaline phosphatase (AP)

EL

HYB 252-08

Trypsin (human)

EL, WB

>1 clone

Trypsin (human), Biotinylated

EL

HYB 021-03B

Specificity

Application

Cat. No.

alpha-Fetoprotein (human, AFP)

EL

>1 clone

Acetylcholinesterase (bovine brain, AChE)

EL, WB

HYB 101-03

Acetylcholinesterase (human brain, AChE)

EL, WB

HYB 111-05

Acetylcholinesterase (human brain, bovine brain, AChE)

EL, WB

HYB 190-01

Amyloid beta-peptide (human)

EL, AP

>1 clone

Butyrylcholinesterase (human, BtChE)

EL

HAH 002-01

Neutrophil gelatinase-associated lipocalin (dog, NGAL)

EL, WB

>1 clone

Neutrophil gelatinase-associated lipocalin (dog, NGAL), Biotinylated

EL

ABS 047-14B

Neutrophil gelatinase-associated lipocalin (human, NGAL)

EL, WB, IH

>1 clone

Neutrophil gelatinase-associated lipocalin (human, NGAL), Biotinylated

EL

>1 clone

Neutrophil gelatinase-associated lipocalin (monkey, human, NGAL)

EL

ABS 038-23

Neutrophil gelatinase-associated lipocalin (mouse, NGAL)

EL, WB

>1 clone

Enzymes

Marker molecules

Neutrophil gelatinase-associated lipocalin (mouse, NGAL), Biotinylated

ABS 043-29B

Neutrophil gelatinase-associated lipocalin (pig, NGAL)

EL, WB

>1 clone

Neutrophil gelatinase-associated lipocalin (pig, NGAL), Biotinylated

EL

ABS 048-28B

Neutrophil gelatinase-associated lipocalin (rat, NGAL)

EL, WB, IH

>1 clone

Neutrophil gelatinase-associated lipocalin (rat, NGAL), Biotinylated

EL

ABS 039-32B

Placental protein 14 (human, PP14, glycodelin A)

EL, IH

>1 clone

Pregnancy-associated plasma protein A (human, PAPP-A)

EL, IH

>1 clone

Procollagen type I C-terminal propeptide (human, PICP)

EL

>1 clone

Procollagen type IIA N-terminal propeptide (human, PIIANP)

EL, IH

BTE 003-02

Specificity

Application

Cat. No.

Clostridium botulinum E toxoid (Botulin E toxoid)

EL

HAV 001-06

Clostridium tetani toxoid (Tetanus toxoid)

EL

>1 clone

Corynebacterium diphtheriae toxoid (Diphtheria toxoid)

EL, WB

>1 clone

Influenza A virus matrix protein

EL, WB

HYB 156-02

Influenza A virus matrix protein, Biotinylated

EL

HYB 156-02B

Microbiology

14

Microbiology (continued) Specificity

Application

Cat. No.

Influenza A virus nucleoprotein

EL, WB

HYB 156-01

Influenza A virus nucleoprotein, Biotinylated

EL

HYB 156-01B

Influenza B virus nucleoprotein

EL, WB

>1 clone

Influenza B virus nucleoprotein, Biotinylated

EL

HYB 116-03B

Mycobacterium tuberculosis Ag85

EL, WB

HYT 27-1

Mycobacterium tuberculosis, ESAT-6

EL, WB

HYB 076-08

Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald)

EL, WB

HBT 10-1

Nitrobacter hamburgensis nitrite oxidoreductase

EL, WB, IH

>1 clone

Pneumolysin

EL, WB

HYB 041-01

Poliovirus type 1

EL

>1 clone

Poliovirus type 2

EL

>1 clone

Poliovirus type 3

EL

>1 clone

Streptolysin

EL

HAB 003-1

Specificity

Application

Cat. No.

Amodiaquine

EL

HYB 320-04

Atrazine

EL

HYB 225-01

Biotin

EL, WB

HYB 212-01

Chloroquine

EL

HYB 317-01

Gliadin peptide

EL

>1 clone

Immunoglobulin heavy chain (chicken, IgY)

EL, WB

HYB 208-03

Immunoglobulin light chain (rat, kappa chain)

EL, AC

MARK 1-1

MHC class I alpha chain (chicken)

WB

KSK 001-03

MHC class II beta chain (chicken)

WB, IH, FC, AP

KSK 001-02

Ovalbumin (chicken)

EL, IP

>1 clone

Ovalbumin (chicken, denatured)

EL, WB

>1 clone

Thioguanine (2-amino-6-mercaptopurine)

EL

>1 clone

Specificity

Application

Cat. No.

Plasminogen activator inhibitor type I (human, PAI-1)

EL, WB, IH, AP

>1 clone

Tissue plasminogen activator (human, tPA)

EL, WB, IH

MON T-1

Urokinase plasminogen activator (human, uPA)

EL, WB, IH, FC

>1 clone

Urokinase plasminogen activator receptor (human, uPAR)

EL, WB, IH, FC

>1 clone

Specificity

Application

Cat. No.

alpha1-Antitrypsin (human, alpha1- AT)

EL, WB

HYB 185-02

alpha1-Antitrypsin (human, alpha1- AT, native and denatured)

EL, WB

HYB 191-01

Albumin, bovine serum (BSA)

EL, WB

HYB 267-01

Albumin, bovine serum (BSA, denatured)

EL

HYB 261-02

Albumin, human serum (HSA)

EL, WB

>1 clone

Miscellaneous

Oncology

Other blood proteins

15

Other blood proteins (continued) Specificity

Application

Cat. No.

Albumin, human serum (HSA, denatured)

EL, WB

HYB 189-01-CS*

Albumin, human serum (HSA, denatured)

EL, WB

HYB 189-09

Apolipoprotein A-1 (human)

EL, WB

HYB 069-01

Apolipoprotein B (human)

EL, WB

>1 clone

beta2-Microglobulin (caiman)

WB

KSK 003-01

beta2-Microglobulin (human)

EL, AP

HYB 290-03

Gc-globulin (human)

EL, WB

>1 clone

Gc-globulin (human), Biotinylated

EL

>1 clone

Gelsolin (human)

EL, WB

ABS 017-20

Haptoglobulin (human)

EL

HYB 170-06

Hemopexin (human)

EL

ABS 013-32

Hemopexin (human), Biotinylated

EL

>1 clone

MDA-treated low-density lipoprotein (human, LDL)

EL, WB

>1 clone

Sera and Antigens Specificity

Cat. No.

Human IgE (non-immune), without azide

DIA HE1

Human IgE (non-immune), with azide

DIA HE1A

Human IgE (non-immune), biotinylated

DIA HE1B

MBL standard serum (human) - 1000 (AU)

SER 101

MBL oligomer deficient serum, B/B genotype (human)

SER 102

SDS-PAGE (16%).

Lane 1: Shows molecular weight markers.

Lane 2: DIA HE1 purified human IgE, 185 kDa. Lane 3: IgE, purified from serum from a myeloma patient.

Human IgE (non-immune) DIA HE1

The DIA HE1 IgE preparation is an affinity-purified, fully human IgE antibody with kappa light chains. The IgE is produced in vitro from a monoclonal hybridoma. This unique source guarantees freedom from contamination by other immunoglobulin isotypes.

Due to its very low batch-to-batch variation, this antibody is suitable as a standard in quantitative IgE assays, used in the field of allergy treatment and diagnostics. Other applications include research in immunochemistry and cellular immunology.

Abbreviations AC

Affinity chromatography

AP

Affinity purification

EL

Enzyme-linked immunosorbent assay (ELISA)

FC

Flow cytometry

IH

Immunohistochemistry

IP

Immunoprecipitation

WB

Western blotting

*Only available as a culture supernatant

16

Alphabetical product index ELISA kits and monoclonal antibodies listed by specificity A α-Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 α1-Antitrypsin (human, α1-AT) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 α1-Antitrypsin (human, α1-AT, native and denatured) . . . . . . . . . . 15 α-Calcitonin gene-related peptide (α-CGRP) . . . . . . . . . . . . . . . . . 13 Acetylcholinesterase (bovine brain, AChE) . . . . . . . . . . . . . . . . . . . . 14 Acetylcholinesterase (human brain, AChE) . . . . . . . . . . . . . . . . . . . . 14 Acetylcholinesterase (human brain, bovine brain, AChE) . . . . . . . 14 Activated protein C-protein C inhibitor (APC-PCI) . . . . . . . . . . . . . . 8 Activated protein C-α1-antitrypsin, neoepitope (human) . . . . . . . . 11 Adrenomedullin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Albumin, bovine serum (BSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Albumin, bovine serum (BSA, denatured) . . . . . . . . . . . . . . . . . . . . 15 Albumin, human serum (HSA) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Albumin, human serum (HSA, denaturated) . . . . . . . . . . . . . . . . . . 16 Alkaline phosphatase (AP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 2-amino-6-mercaptopurine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Amodiaquine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Amyloid-β peptide (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Antithrombin III (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Antithrombin III (human, denatured) . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Antithrombin III (human, native and denatured) . . . . . . . . . . . . . . . . 11 APC-AAT complexes, neoepitope (human) . . . . . . . . . . . . . . . . . . . . 11 APC-PCI . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 8 Apolipoprotein A-1 (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Apolipoprotein B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Aprotinin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Atrazine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

D D-dimer (human, dog) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 DBP (human, Vitamin-D binding protein) . . . . . . . . . . . . . . . . . . . . . 16 Diphtheria toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Dog NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14

E Estradiol-17β . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Exendin-4 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13

F

B β1H-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 β2-Microglobulin (caiman) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 β2-Microglobulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Biotin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Botulin E toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 BSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 BSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Butyrylcholinesterase (human, BtChE) . . . . . . . . . . . . . . . . . . . . . . . . 14

C Calcitonin-gene related peptide (human, CGRP) . . . . . . . . . . . . . . 13 Chloroquine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Chorionic gonadotrophin (human, hCG) . . . . . . . . . . . . . . . . . . . . . . 13 Christmas factor (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Clostridium botulinum E toxoid (Botulin E toxoid) . . . . . . . . . . . . . . 14 Clostridium tetani toxoid (Tetanus toxoid) . . . . . . . . . . . . . . . . . . . . . 14 Coagulation factor IX (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Collagen Type I (human, bovine, pig, sheep, dog, goat) . . . . . . . . 10 Collagen Type III (human, dog, rat, kangaroo) . . . . . . . . . . . . . . . . 10 Collagen Type V (human, dog, sheep, pig, kangaroo, rabbit, bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Collectin-43 (bovine, CL-43) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C1-inhibitor (human, C1-INH) . . . . . . . . 11 Complement component C1s (human, pro- and activated enzyme) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C2 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C3 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11

17

Complement component C3 (human), β-chain genetic variant . . . 11 Complement component C3 (rat) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C3a/C3a desArg (human) . . . . . . . . . . . . 11 Complement component C4 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C5 (human) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C5a/C5a (desArg) anaphylatoxin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Complement component C5b-9 (human) . . . . . . . . . . . . . . . . . . . . . 12 Complement component C9 (human) . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor B (caiman) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor B (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor B (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor D (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Complement factor H (human, ß1H-globulin) . . . . . . . . . . . . . . . . . 12 Complement factor I (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Conglutinin (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Corynebacterium diphtheriae toxoid (Diphtheria toxoid) . . . . . . . . 14

Diagnostics

Factor IX (human, Christmas factor) . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Fetoprotein (human, AFP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Fibrinogen (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Fibronectin (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Fibronectin (bovine, human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Fibronectin (bovine, human, chicken) . . . . . . . . . . . . . . . . . . . . . . . . 10 Fibronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Ficolin-H (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Ficolin-L (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Ficolin-M (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

G Gastric inhibitory polypeptide (human, GIP) . . . . . . . . . . . . . . . . . . 13 Gc-globulin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Gelsolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Ghrelin (human, rat) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Gliadin peptide . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Glucagon-like peptide-1 (GLP-1(1-36)amide, N-terminal-extension specific) . . . . . . . . . . . 13 Glucagon-like peptide-1 (GLP-1(7-36)amide, C-terminal specific) . . . . . . . . . . . . . . . . . . . . . 13 Glucagon-like peptide-1 (GLP-1(7-37) and GLP-1(7-36)amide, N-terminal specific) . . . . . . 13 Glucagon-like peptide-1 (GLP-1(9-37) and GLP-1(9-36)amide, N-terminal specific) . . . . . . . . . . . . . . . . . . . . . . 13 Glucagon-like peptide-1 (GLP-1, Mid-molecule specific) . . . . . . 13

Glucagon-like peptide-1 (GLP-1, non-amidated (-Arg-Gly), C-terminal specific) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 Glucagon-like peptide-2 (human, GLP-2) . . . . . . . . . . . . . . . . . . . . 13 Glycodelin A (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Glycoprotein-340 (human, gp-340) . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

H Haptoglobin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Hemopexin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 hCG . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 H-Ficolin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Hirudin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 HNL (human neutrophil lipocalin) . . . . . . . . . . . . . . . . . . . . . . 3, 5, 6, 14 HSA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 HSA, denatured . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 hSP-A . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 hSP-D . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Human IgE (non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16

I IgE (human, non-immune) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 IgG/k control antibody . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Immunoglobulin heavy chain (chicken, IgY) . . . . . . . . . . . . . . . . . . . 15 Immunoglobulin light chain (rat, κ chain) . . . . . . . . . . . . . . . . . . . . . 15 Influenza A virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14, 15 Influenza B virus . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14, 15

L LDL, (human, MDA-treated) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Leptin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 13 L-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Lipocalin-2 (human, dog, mouse, pig, rat) . . . . . . . . . . . . . 3, 5, 6, 14

M Mannan-binding lectin (chicken, MBL) . . . . . . . . . . . . . . . . . . . . . . . 12 Mannan-binding lectin (human, horse, pig, MBL) . . . . . . . . . . . . . 12 Mannan-binding lectin (human, MBL) . . . . . . . . . . . . . . . . . . . . . . 9, 12 Mannan-binding lectin (rat, MBL) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 MBL standard serum (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 16 MBL Oligomer deficient serum (human) . . . . . . . . . . . . . . . . . . . . . . 16 MDA treated low-density lipoprotein (human, LDL) . . . . . . . . . . . . 16 M-Ficolin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 MHC class I α chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 MHC class II β chain (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Monkey NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14 Mouse NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14 Mycobacterium tuberculosis, Ag85 . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Mycobacterium tuberculosis, ESAT-6 . . . . . . . . . . . . . . . . . . . . . . . . 15 Mycobacterium tuberculosis, L-alanine dehydrogenase (Ald) . . . 15

N Neuropeptide Y (human, rat, mouse, NPY) . . . . . . . . . . . . . . . . . . . 13 NGAL (dog, neutrophil gelatinase-associated lipocalin) . . . . . . . . . 7, 14 NGAL (human, neutrophil gelatinase-associated lipocalin) . 3, 5, 6, 14 NGAL (monkey, neutrophil gelatinase-associated lipocalin) . . . . . 7, 14 NGAL (mouse, neutrophil gelatinase-associated lipocalin) . . . . . . 7, 14 NGAL (pig, neutrophil gelatinase-associated lipocalin) . . . . . . 7, 14 NGAL (rat, neutrophil gelatinase-associated lipocalin) . . . . . . . 7, 14 Nitrobacter hamburgensis nitrite oxidoreductase . . . . . . . . . . . . . 15

O Ovalbumin (chicken) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Ovalbumin (chicken, denatured) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15

P PAI-1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Pancreatic polypeptide (human, PP) . . . . . . . . . . . . . . . . . . . . . . . . 13 Peptide histidine-methionine (human, PHM) . . . . . . . . . . . . . . . . . . 14 Peptide YY (human, PYY) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Perlecan (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Pig NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14 Placental protein 14 (human, PP14, glycodelin A) . . . . . . . . . . . . . . 14 Plasminogen activator inhibitor type 1 (human, PAI-1) . . . . . . . . . 15 Pneumolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Poliovirus type 1 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Poliovirus type 2 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Poliovirus type 3 . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Pregnancy-associated plasma protein A (human, PAPP-A) . . . . . 14 Procollagen type I C-terminal propeptide (human, PICP) . . . . . . . 14 Procollagen type IIA N-terminal propeptide (human, PIIANP) . . . 14 Properdin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12 Protein C (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Protein S (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

R Rat NGAL . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 7, 14

S Streptolysin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15 Surfactant protein A (human, hSP-A) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Surfactant protein D (human, hSP-D) . . . . . . . . . . . . . . . . . . . . . . . . . 11 Siderocalin . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3, 5, 6, 7, 14

T Tetanus toxoid . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Tetranectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 The NGAL TestTM . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 3 Thioguanine (2-amino-6-mercaptopurine) . . . . . . . . . . . . . . . . . . . . 15 Thrombin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 11 Thrombospondin I (bovine) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Tissue plasminogen activator (human, tPA) . . . . . . . . . . . . . . . . . . 15 Trypsin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Tumor necrosis factor α (human, TNF-α) . . . . . . . . . . . . . . . . . . . . . . 14

U Urokinase plasminogen activator (human, uPA) . . . . . . . . . . . . . . . 15 Urokinase plasminogen activator receptor (human, uPAR) . . . . . 15

V Vasoactive intestinal peptide (human, bovine, porcine, rat, VIP) . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14 Vitamin-D binding protein (human) . . . . . . . . . . . . . . . . . . . . . . . . . . 16 Vitronectin (bovine, horse, rabbit) . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Vitronectin (bovine, sheep) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Vitronectin (human) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10 Vitronectin (human, dog, cat, rabbit, bovine) . . . . . . . . . . . . . . . . . 10 Vitronectin (human, dog, cat, sheep) . . . . . . . . . . . . . . . . . . . . . . . . . 10 von Willebrand factor (human, vWf) . . . . . . . . . . . . . . . . . . . . . . . . . . . 11

18 Diagnostics

Ordering information Products should be ordered from your local BioPorto Diagnostics distributor, please see www.bioporto.com/how_to_buy.

If there is no distributor in your country, please order directly from BioPorto Diagnostics.

BioPorto Diagnostics A/S Grusbakken 8 DK-2820 Gentofte Denmark VAT number DK-1864 5882 Phone (+45) 4529 0000 Fax (+45) 4529 0001 Mail info@bioporto.com Web www.bioporto.com

Terms and conditions Returns No returns can be accepted without prior written approval by the ordering channel (distributor or BioPorto Diagnostics A/S). Only unopened merchandise that has been handled and stored as prescribed can be returned.

No return of custom manufactured products will be authorized if the product meets the specifications agreed upon prior to shipment.

Alternate right BioPorto Diagnostics A/S reserves the right to change product specifications (e.g. buffer system) to maximize product quality.

Storage Directions given on an individual datasheet or label are an integral part of these terms and conditions and must be strictly followed.

Reservation of title Unless otherwise marked, all products are for research use or further manufacture only. Not for use in diagnostic procedures. Not for use in human therapeutic applications.

Product codes: GAU*, MON* and DIA 011-01B, are not for further manufacture either.

Products sold for in vitro diagnostic use are CE-marked and comply with EU Directive 98/79/EC and Canadian Medical Device Regulations. In vitro diagnostic products are available in selected countries, see www.bioporto.com for availability in your country.

The foregoing is in lieu of all warranties, expressed or implied, including implied warranties of merchantability and fitness for a particular purpose. In no event shall BioPorto Diagnostics be responsible for loss of profits or indirect consequential losses resulting from use of its products.

For more information contact your local distributor or BioPorto Diagnostics A/S.

19

Diagnostics

BioPorto develops and markets antibodies and antibody-based products, including tests to diagnose human disease, both for the benefit of individual patients and to promote efficiency in the health sector.

The Company’s developments include a test (NGAL) to diagnose and monitor acute kidney damage. www.bioporto.com

BioPorto Diagnostics A/S Grusbakken 8 DK-2820 Gentofte Denmark

Phone Fax E-mail Web

(+45) 4529 0000 (+45) 4529 0001 info@bioporto.com www.bioporto.com www.ngal.com 20 Diagnostics

70004/032011/e

Diagnostics